Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Watertown’s Selecta will license technology to speed gene therapy development

By , Globe Staff

Selecta will license its synthetic vaccine particles technology to Philadephia-based Spark for use in experimental gene therapies targeting hemophilia.

If US companies bring back billions from overseas, who profits?

By , Globe Staff

US companies might bring back billions if Trump cuts corporate taxes, but they probably won’t use the money to create jobs or do more drug research.

Boston biotech Acetylon being acquired by Celgene

By , Globe Staff

Privately held Boston biotech company Acetylon Pharmaceuticals Inc., which is developing drugs to treat blood cancer and other diseases.

Bluebird shares soar 17 percent on multiple myeloma trial

By Robert Weisman , Globe Staff

The Cambridge biotech reported encouraging results from an early-stage study of its experimental cancer immunotherapy.